tert-Butyl (3-((4-((tert-butoxycarbonyl)amino)butyl)amino)propyl)carbamate

Catalog No. :
ACLWFX602
CAS No. :
83392-10-3
Molecular Formula :
C17H35N3O4
Molecular Weight :
345.48

IUPAC Name:tert-butyl (4-((3-((tert-butoxycarbonyl)amino)propyl)amino)butyl)carbamate

tert-Butyl (3-((4-((tert-butoxycarbonyl)amino)butyl)amino)propyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$54.00Login to see priceIn stockInquiry
250mg97%$112.00Login to see priceIn stockInquiry
1g97%$346.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (3-((4-((tert-butoxycarbonyl)amino)butyl)amino)propyl)carbamate
IUPAC Nametert-butyl (4-((3-((tert-butoxycarbonyl)amino)propyl)amino)butyl)carbamate
MDL No.0
Molecular FormulaC17H35N3O4
Molecular Weight345.48
SMILESCC(C)(C)OC(=O)NCCCCNCCCNC(=O)OC(C)(C)C
InChI KeyIGJAYGNJQNIACJ-UHFFFAOYSA-N
Synonym13-Oxa-2,6,11-triazapentadecanoic acid, 14,14-dimethyl-12-oxo-,1,1-dimethylethyl ester;N1,N3-DiBoc-spermidine;tert-Butyl (3-((4-((tert-butoxycarbonyl)amino)butyl)amino)propyl)carbamate
CAS No.83392-10-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACLWFX602 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBTJY967 route compound structure diagram
    ACBTJY967334-50-9 In Stock
  2. Then
  3. ACLWFX602 route product structure diagram
    ACLWFX60283392-10-3 In Stock
Inquiry

2. ACLWFX602 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBRAJ163 route compound structure diagram
    ACBRAJ16333545-98-1 In Stock
  4. Then
  5. ACLWFX602 route product structure diagram
    ACLWFX60283392-10-3 In Stock
Inquiry

Comments (0)